<code id='4E3C6F33FF'></code><style id='4E3C6F33FF'></style>
      • <acronym id='4E3C6F33FF'></acronym>
      <center id='4E3C6F33FF'><center id='4E3C6F33FF'><tfoot id='4E3C6F33FF'></tfoot></center><abbr id='4E3C6F33FF'><dir id='4E3C6F33FF'><tfoot id='4E3C6F33FF'></tfoot><noframes id='4E3C6F33FF'>
      • <optgroup id='4E3C6F33FF'><strike id='4E3C6F33FF'><sup id='4E3C6F33FF'></sup></strike><code id='4E3C6F33FF'></code></optgroup>
        5. <b id='4E3C6F33FF'><label id='4E3C6F33FF'><select id='4E3C6F33FF'><dt id='4E3C6F33FF'><span id='4E3C6F33FF'></span></dt></select></label></b><u id='4E3C6F33FF'></u>
          <i id='4E3C6F33FF'><strike id='4E3C6F33FF'><tt id='4E3C6F33FF'><pre id='4E3C6F33FF'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / explore      
           
     
           
      
          explore 
           
      
           
      
           
       2025-10-01 21:55:36 
   
      
           
      
           
                        
          explore  
          
                                   
                 
                                      author：hotspot   
                                        
                                      
                                      Page View：1
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Argenx readies a blockbuster opportunity with drug for autoimmune disease
                                
                            
          Next article：  
                                      
                                          Medical leaders decry Supreme Court decision on affirmative action
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles